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Polychlorinated Biphenyls
Inhibit Amyloid Fibril Formation
n
In this issue of Chemistry & Biology, Purkey et al. [1] o
compare the binding of PCBs and hydroxylated PCBs t(polychlorinated biphenyls) with the human serum t
protein transthyretin. Hydroxylated PCBs appear to b
bind with higher selectivity to transthyretin relative to o
other serum proteins and in so doing inhibit amyloid s
fibril formation. b
c
The report by Purkey et al. [1], in this issue marks a p
comeuppance for PCBs—specifically, hydroxylated
PCBs. PCBs were first used commercially in the U.S. in t
1929 and soon became practically indispensible in flu- t
ids applications where thermal resistance and low con- s
ductivity are essential, e.g., heat transfer, hydraulics, c
and capacitors. By the 1960s there was mounting evi- c
dence for PCB toxicity. As the extraordinary environ- b
mental persistence of PCBs became apparent, U.S. m
production was finally banned in 1977. Arguably, PCBs t
have become the molecular poster child for environ- d
mental accumulation. Since PCBs will remain in the en- r
fvironment for many decades, significant efforts haveeen made to identify the most harmful PCBs and their
echanisms of toxicity.
PCBs were manufactured and used as mixtures of
everal dozen of the 209 possible congeners. Unfortu-
ately, these mixtures of PCBs exert pleiotropic physi-
logical effects that are difficult to tease apart. The
oxicology of PCBs is further complicated by their me-
abolism into hydroxylated PCBs with a vague resem-
lance to estrogens and thyroxin (Figure 1). A number
f PCBs and hydroxylated PCBs have been previously
hown to bind to transthyretin in vitro, but there has
een little direct information about the binding of these
ompounds to transthyretin in serum where various
roteins compete for lipophilic ligands [2–4].
Transthyretin is a homotetrameric protein that serves
wo functions in humans. The transthyretin tetramer
ransports up to two molecules of thyroxin in a con-
tricted tunnel formed at the tetramer interface. A se-
ond function of the transthyretin tetramer is the asso-
iation with retinol binding protein (RBP), which is
elieved to protect RBP and its retinol ligand from glo-
erular filtration in the kidneys. Unfortunately, the
ransthyretin tetramer is poised to malfunction. The
issociation of monomeric subunits from the transthy-
etin tetramer is the rate-determining step toward mis-
olding and misassembly into amyloidogenic plaques.
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amyloidosis, familial amyloid cardiomyopathy, and the
familial amyloid polyneuropathies—collectively referred
to as ATTR. Senile systemic amyloidosis is associated
with wild-type transthyretin and slow onset, whereas
the familial amyloidoses are associated with genetic
mutations that can lead to symptoms in patients aged
in their 30s or 40s. In the worst cases, familiar cardio-
myopathy presents as congestive heart failure. Neuro-
pathic symptoms include diminished sensation and or
pain, particularly in the extremities. Unfortunately, the
only treatment available for ATTR is to transplant the
liver, which is the source of transthyretin.
Surprisingly, the thyroxin binding function of the
transthyretin tetramer does not appear to be necessary
for either thyroxin transport or RBP binding, so efforts
have been directed toward the identification of ligands
that bind to and stabilize the tetrameric native state of
transthyretin, thereby inhibiting monomer dissociation
[5, 6]. Thus, PCBs that bind to the transthyretin tetra-
mer and inhibit disassembly could serve as leads for
the development of inhibitors of transthyretin amyloido-
genesis.
Purkey and coworkers carried out two signficant
assays on 22 PCBs—8 PCBs reported to bind tightly
(KD < 50 nM) to transthryetin and 14 4-hydroxy-PCBs.
An antibody capture assay was used to assess binding
stoichiometry in human serum where proteins like albu-
min and thyroxin binding protein can compete for bind-
ing. PCBs that bound to the transthyretin tetramer with
stoichiometries closest to the theoretical upper limit of
2:1 PCB/tetramer were deemed most selective for
transthyretin over other proteins. All 14 of the hydroxyl-
ated PCBs exhibited binding stoichiometries between
0.7 and 1.9 ligand/transthyretin, only 2 of the 8 PCBs
(3,3#,5,5#-tetrachlorobiphenyl and 3,3#,4,5,5#-pentachlo-
robiphenyl 3) appeared to bind appreciably to transthyre-
tin. While the binding stoichiometries that were measured
are actually lower limits, the data suggest that the hydrox-
ylated PCBs bind selectively to the transthyretin tetramer,
whereas un-hydroxylated PCBs do not.
The hydroxylated PCBs were assayed for the ability to
inhibit acid-induced amyloid fibril formation. All of the hy-
droxylated PCBs inhibited fibril formation when added to
3.6 M transthyretin at equimolar concentration; three of
them appeared even more effective than the analgesicFigure 1. Structures of Ligands for the Transthyretin Tetramerflufenamic acid, a promising inhibitor of transthyretin am-
yloid fibril formation [7]. The results are consistent with
the idea that ligand binding can lead to kinetic stabiliza-
tion of the tetramer.
In order to triangulate structural data with the serum
binding data and the fibril inhibition data, cocrystal struc-
tures were obtained with four of the hydroxylated PCBs
bound pairwise in the transthyretin tetramers. The best
fibril inhibitor, 4,4#-dihydroxy-3,3#5,5#-tetrachlorobiphenyl
18 adopts a nonplanar conformation that places each of
the four chlorine substituents in one of the four halogen
binding pockets of the transthyretin tetramer.
The most deeply bound of the two phenolic groups en-
gages two of the four subunits in a hydrogen bonding
network (Figure 2). The network connects the phenolic
hydroxyl, with bound waters and the Ser117 sidechains
on opposing transthyretin subunits. In contrast, in the
crystal structure of the transthyretin•thyroxin2 complex
1IE4.pdb, the phenolic hydroxyl group of thyroxin is not
observed to engage in such a network. Instead, the thy-
roxin hydroxyl forms a hydrogen bond to water which is
in turn hydrogen bonded to Thr119.
The results reported by Purkey et al. in this issue chal-
lenge the traditional notion that PCBs have no beneficial
physiological effects. While the simple hydroxylated
PCBs studied in this work are not yet ready for the clinic,
they do provide useful information for the design of im-
proved inhibitors of transthyretin amyloid fibril formation.
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